Physician profile
Prasad V Kandula
NPI 1164518460
$12,894.39
in general payments reported to CMS, 2019-2025
44 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,106 · 2020: $770 · 2021: $2,150 · 2022: $1,771 · 2023: $2,168 · 2024: $2,645 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,098.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,594.17 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $1,320.14 | 2021-2024 | Linq II, Micra, In.Pact Av |
| Novartis Pharmaceuticals Corporation | $1,256.06 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,232.66 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $821.18 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $704.32 | 2019-2025 | Watchman Access System, Rotablator Rotational Atherectomy System Console Kit, Lux-Dx Insertable Cardiac Monitor |
| Abiomed | $662.15 | 2021-2025 | Impella |
| Pfizer INC. | $605.07 | 2019-2025 | |
| Abbott Laboratories | $547.16 | 2019-2024 | Aveir, Ensite, Jot Dx |
| Chiesi USA, INC. | $518.12 | 2019-2025 | Kengreal, Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $513.90 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $377.83 | 2021-2025 | Verquvo |
| Shockwave Medical, INC | $373.23 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.85 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $316.43 | 2019-2024 | Brilinta, Farxiga |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Kandula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.